Stem Cell Therapy Market (By Product: Adult Stem Cells (ASCs), Human Embryonic Stem Cells (HESCs), Induced Pluripotent Stem Cells (iPSCs), Very Small Embryonic Like Stem Cells; By Therapy Type; By Application; By Technology; By End User)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global Stem Cell Therapy market size was exhibited at USD 12.9 billion in 2022 and is projected to hit around USD 46.74 billion by 2032, growing at a CAGR of  13.74% during the forecast period 2023 to 2032.

Stem Cell Therapy market size

Key Takeaways:

  • By product, the adult stem cells (ASCs) segment has reached 86.9% revenue share in 2022
  • The induced pluripotent stem cells (iPSCs) segment is predicted to grow at a CAGR of 9.6% between 2022 to 2032
  • By application, the regenerative medicine segment has garnered 92% in 2022
  • The drug discovery and development application segment is projected to grow at a CAGR of 9.6% from 2023 to 2032
  • By therapy, allogenic stem cell therapy has hit market share of 59.5% in 2022
  • North America accounted for the largest market share of 54% in 2022
  • Asia Pacific is expected to grow at a CAGR of 9.3% between 2023 to 2032

Stem Cell Therapy Market Report Scope

Report Coverage

Details

Market Size in 2023

USD 14.67 Billion

Market Size by 2032

USD 46.74 Billion

Growth Rate From 2023 to 2032

CAGR of  13.74%

Base Year

2022

Forecast Period

2023 to 2032

Segments Covered

Product, Therapy Type, Application, Technology, End User, Geography

Market Analysis (Terms Used)

Value (US$ Million/Billion) or (Volume/Units)

Regional Scope

North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa

Key Companies Profiled

Caladrius, CELGENE CORPORATION, ReNeuron Group plc, Virgin Health Bank, Opexa Therapeutics, Inc., Pluristem Therapeutics Inc, STEMCELL Technologies Inc., Biovault family, Precious Cells International, Ltd, Mesoblast Ltd,  Seneca Biopharmaceuticals, Inc.

Stem Cell Therapy Market Dynamics

 Drivers: Availability of funding for stem cell research

Stem cell research funding has strengthened in the past few years, attributed to the need for novel therapeutic interventions in patients with cardiovascular, neurological, and autoimmune disorders. The NIH funding for stem cell research reached its highest peak in 2018 and has shown a year-on-year growth of more than 5% in the stem cell research funding each year. This trend is expected to continue with the increase in funding initiatives announced in 2021. For instance, in September 2021, the California Institute for Regenerative Medicine granted a grant of USD 31 million to Stanford Research for launching first-in-human trials of stem cells in the treatment of heart failure, stroke, and spinal cord tumours.

Restraints: Ethical concerns related to embryonic stem cells

Studies exploring the therapeutic potential of embryonic stem cells (ESC) are associated with various ethical issues attributed to the destruction of human embryos. Lack of proper federal policies that define what can be funded in embryo-based stem cell research or therapy development may restrain the market's expansion in the future to a certain extent. In addition, the complexities of regulations in this area require federal guidelines that can support researchers, scientists, and pharmaceutical companies to develop ESC therapy and further facilitate its commercialization.

Type Insights

Depending upon the type, the allogeneic stem cell therapy segment accounted for about 59.5% in the 2022. As the allergenic stem cell segment has seen a growing demand in the past which is due to the usage in treatment against cancer and the growing number of cases of this dreadful disease will create a greater demand in the coming years. With the help of the immune system cells the cancerous cells can be killed and these cells can be acquired from a donor. The segment is expected to grow well in the coming years due to its increased application for treating different types of cancers like leukemia lymphoma and myeloma.

Apart from the growing demand for to allogeneic segment the autologous segment is also expected to grow well in the coming years the autologous therapy segment is expected to grow at a higher compound annual growth rate in the coming years. As the use of this therapy reduces the chances of complications the market is expected to grow well. Also, the use of this therapy is expected to grow well in the coming years due to the lower chances of the rejection of the graft. The use of this treatment has largely affected the market as the survival rates have increased. This segment is expected to grow well in the coming years as it is affordable as compared to the other type. This happens to be a low-risk alternative.

Application Insights

Depending upon the basis of application, the region relative medicine segment is expected to have the largest share in the market in the coming years. The segment has dominated the market in the past with a share of about 92% and it is expected to grow well in the coming years. The demand for regenerative medicine especially for the neurological disorders is expected to grow in the coming years as that has been an increased number of approvals that are associated with the clinical trials for treating different types of diseases. Governments of various nations are increasing their investments for developing the regenerative medicines. These medicines will be helpful in treating different chronic disorders, diabetes, heart disease and blood disorder.

Apart from the growing demand of the stem cell therapy or the stem cells market for various regenerative medicines they shall be good demand for the development and the discovery of the drugs.

End User Insights

On the basis of the end user, the hospital segment is expected to have a dominant position in the coming years. The way level infrastructure and the different types of treatment options will help in the growth of the market in the coming years. As the hospitals have been instrumental in providing good treatment to the patience due to their association with the various research institutes which help them in coming up with novel therapies against various diseases these collaborations have being extremely favorable for the growth of the market in the past and they shall be instrumental in developing the market in the future.

Regional Insights

The North American region has dominated the market in the past and it is expected to have a dominant position even in the coming years. This region had a share of about 53% in the past as major manufacturing units are present in the North American region. The availability of the research and development units and advanced infrastructure in the healthcare segment shall be instrumental in the growth of the market. Constant reforms in this nation that are supportive for the healthcare sector and the presence of favorable reimbursement policies will play a great role in the growth of the market. Initiatives taken by the government in the United States are highly favorable for the research activities.

Constant promotion and awareness regarding the use of this therapies for various diseases through these organizations will be instrumental in increasing the demand for the treatment. The Asia Pacific region is also expected to grow well in the coming years and it is expected to grow at the highest compound annual growth rate of about 9.2% in the coming years. Favorable initiatives from the government and increased research activities will be helpful in the development of the stem cell treatments market in the Asia Pacific region.

Some of the prominent players in the Stem Cell Therapy Market include:

  • Caladrius
  • CELGENE CORPORATION
  • ReNeuron Group plc
  • Virgin Health Bank
  • Opexa Therapeutics, Inc.
  • Pluristem Therapeutics Inc
  • STEMCELL Technologies Inc.
  • Biovault family
  • Precious Cells International Ltd
  • Mesoblast Ltd
  • Seneca Biopharmaceuticals, Inc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Stem Cell Therapy market.

By Product

  • Adult Stem Cells (ASCs)
    • Hematopoietic
    • Mesenchymal
    • Neural
    • Epithelial/Skin
    • Others
  • Human Embryonic Stem Cells (HESCs)
  • Induced Pluripotent Stem Cells (iPSCs)
  • Very Small Embryonic Like Stem Cells

By Therapy Type

  • Autologous
  • Allergenic

By Application

  • Regenerative Medicine
    • Neurology
    • Orthopedics
    • Oncology
    • Hematology
    • Cardiovascular and Myocardial Infraction
    • Injuries
    • Diabetes
    • Liver Disorder
    • Incontinence
    • Others
  • Drug Discovery and Development

By Technology

  • Cell Acquiition
    • Bone Marrow Harvest
    • Umbilical Blood Cord
    • Apheresis
  • Cell Production
    • Therapeutic Cloning
    • In-vitro Fertilization
    • Cell Culture
    • Isolation
  • Cryopreservation
  • Expansion and Sub-Culture

By End User

  • Hospitals
  • Research institutes
  • surgical institutes
  • Orders

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Stem Cell Therapy Market 

5.1. COVID-19 Landscape: Stem Cell Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Stem Cell Therapy Market, By Product

8.1. Stem Cell Therapy Market, by Product, 2023-2032

8.1.1. Adult Stem Cells (ASCs)

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Human Embryonic Stem Cells (HESCs)

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Induced Pluripotent Stem Cells (iPSCs)

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Very Small Embryonic Like Stem Cells

8.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Stem Cell Therapy Market, By Therapy Type

9.1. Stem Cell Therapy Market, by Therapy Type, 2023-2032

9.1.1. Autologous

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Allergenic

9.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Stem Cell Therapy Market, By Application 

10.1. Stem Cell Therapy Market, by Application, 2023-2032

10.1.1. Regenerative Medicine

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Drug Discovery and Development

10.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Stem Cell Therapy Market, By Technology

11.1. Stem Cell Therapy Market, by Technology, 2023-2032

11.1.1. Cell Acquiition

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Cell Production

11.1.2.1. Market Revenue and Forecast (2020-2032)

11.1.3. Cryopreservation

11.1.3.1. Market Revenue and Forecast (2020-2032)

11.1.4. Expansion and Sub-Culture

11.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Stem Cell Therapy Market, By End User

12.1. Stem Cell Therapy Market, by End User, 2023-2032

12.1.1. Hospitals

12.1.1.1. Market Revenue and Forecast (2020-2032)

12.1.2. Research institutes

12.1.2.1. Market Revenue and Forecast (2020-2032)

12.1.3. surgical institutes

12.1.3.1. Market Revenue and Forecast (2020-2032)

12.1.4. Orders

12.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 13. Global Stem Cell Therapy Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Product (2020-2032)

13.1.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.1.3. Market Revenue and Forecast, by Application (2020-2032)

13.1.4. Market Revenue and Forecast, by Technology (2020-2032)

13.1.5. Market Revenue and Forecast, by End User (2020-2032)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Product (2020-2032)

13.1.6.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.1.6.3. Market Revenue and Forecast, by Application (2020-2032)

13.1.6.4. Market Revenue and Forecast, by Technology (2020-2032)

13.1.6.5. Market Revenue and Forecast, by End User (2020-2032)

13.1.7.  Rest of North America

13.1.7.1.  Market Revenue and Forecast, by Product (2020-2032)

13.1.7.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.1.7.3. Market Revenue and Forecast, by Application (2020-2032)

13.1.7.4. Market Revenue and Forecast, by Technology (2020-2032)

13.1.7.5. Market Revenue and Forecast, by End User (2020-2032)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Product (2020-2032)

13.2.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.2.3. Market Revenue and Forecast, by Application (2020-2032)

13.2.4. Market Revenue and Forecast, by Technology (2020-2032)

13.2.5. Market Revenue and Forecast, by End User (2020-2032)

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Product (2020-2032)

13.2.6.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.2.6.3. Market Revenue and Forecast, by Application (2020-2032)

13.2.6.4. Market Revenue and Forecast, by Technology (2020-2032)

13.2.6.5. Market Revenue and Forecast, by End User (2020-2032)

13.2.7.  Germany

13.2.7.1. Market Revenue and Forecast, by Product (2020-2032)

13.2.7.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.2.7.3.  Market Revenue and Forecast, by Application (2020-2032)

13.2.7.4. Market Revenue and Forecast, by Technology (2020-2032)

13.2.7.5. Market Revenue and Forecast, by End User (2020-2032)

13.2.8.  France

13.2.8.1. Market Revenue and Forecast, by Product (2020-2032)

13.2.8.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.2.8.3. Market Revenue and Forecast, by Application (2020-2032)

13.2.8.4. Market Revenue and Forecast, by Technology (2020-2032)

13.2.8.5.  Market Revenue and Forecast, by End User (2020-2032)

13.2.9. Rest of Europe

13.2.9.1. Market Revenue and Forecast, by Product (2020-2032)

13.2.9.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.2.9.3. Market Revenue and Forecast, by Application (2020-2032)

13.2.9.4. Market Revenue and Forecast, by Technology (2020-2032)

13.2.9.5.  Market Revenue and Forecast, by End User (2020-2032)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Product (2020-2032)

13.3.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.3.3. Market Revenue and Forecast, by Application (2020-2032)

13.3.4. Market Revenue and Forecast, by Technology (2020-2032)

13.3.5. Market Revenue and Forecast, by End User (2020-2032)

13.3.6.  India

13.3.6.1. Market Revenue and Forecast, by Product (2020-2032)

13.3.6.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.3.6.3. Market Revenue and Forecast, by Application (2020-2032)

13.3.6.4. Market Revenue and Forecast, by Technology (2020-2032)

13.3.6.5. Market Revenue and Forecast, by End User (2020-2032)

13.3.7. China

13.3.7.1. Market Revenue and Forecast, by Product (2020-2032)

13.3.7.2.  Market Revenue and Forecast, by Therapy Type (2020-2032)

13.3.7.3. Market Revenue and Forecast, by Application (2020-2032)

13.3.7.4. Market Revenue and Forecast, by Technology (2020-2032)

13.3.7.5. Market Revenue and Forecast, by End User (2020-2032)

13.3.8. Japan

13.3.8.1. Market Revenue and Forecast, by Product (2020-2032)

13.3.8.2.  Market Revenue and Forecast, by Therapy Type (2020-2032)

13.3.8.3. Market Revenue and Forecast, by Application (2020-2032)

13.3.8.4. Market Revenue and Forecast, by Technology (2020-2032)

13.3.8.5. Market Revenue and Forecast, by End User (2020-2032)

13.3.9. Rest of APAC

13.3.9.1. Market Revenue and Forecast, by Product (2020-2032)

13.3.9.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.3.9.3. Market Revenue and Forecast, by Application (2020-2032)

13.3.9.4. Market Revenue and Forecast, by Technology (2020-2032)

13.3.9.5. Market Revenue and Forecast, by End User (2020-2032)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Product (2020-2032)

13.4.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.4.3. Market Revenue and Forecast, by Application (2020-2032)

13.4.4. Market Revenue and Forecast, by Technology (2020-2032)

13.4.5. Market Revenue and Forecast, by End User (2020-2032)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Product (2020-2032)

13.4.6.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.4.6.3.  Market Revenue and Forecast, by Application (2020-2032)

13.4.6.4. Market Revenue and Forecast, by Technology (2020-2032)

13.4.6.5. Market Revenue and Forecast, by End User (2020-2032)

13.4.7. North Africa

13.4.7.1. Market Revenue and Forecast, by Product (2020-2032)

13.4.7.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.4.7.3. Market Revenue and Forecast, by Application (2020-2032)

13.4.7.4. Market Revenue and Forecast, by Technology (2020-2032)

13.4.7.5. Market Revenue and Forecast, by End User (2020-2032)

13.4.8. South Africa

13.4.8.1. Market Revenue and Forecast, by Product (2020-2032)

13.4.8.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.4.8.3. Market Revenue and Forecast, by Application (2020-2032)

13.4.8.4. Market Revenue and Forecast, by Technology (2020-2032)

13.4.8.5. Market Revenue and Forecast, by End User (2020-2032)

13.4.9. Rest of MEA

13.4.9.1. Market Revenue and Forecast, by Product (2020-2032)

13.4.9.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.4.9.3. Market Revenue and Forecast, by Application (2020-2032)

13.4.9.4. Market Revenue and Forecast, by Technology (2020-2032)

13.4.9.5. Market Revenue and Forecast, by End User (2020-2032)

13.5.  Latin America

13.5.1. Market Revenue and Forecast, by Product (2020-2032)

13.5.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.5.3. Market Revenue and Forecast, by Application (2020-2032)

13.5.4. Market Revenue and Forecast, by Technology (2020-2032)

13.5.5. Market Revenue and Forecast, by End User (2020-2032)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Product (2020-2032)

13.5.6.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.5.6.3. Market Revenue and Forecast, by Application (2020-2032)

13.5.6.4. Market Revenue and Forecast, by Technology (2020-2032)

13.5.6.5. Market Revenue and Forecast, by End User (2020-2032)

13.5.7. Rest of LATAM

13.5.7.1. Market Revenue and Forecast, by Product (2020-2032)

13.5.7.2. Market Revenue and Forecast, by Therapy Type (2020-2032)

13.5.7.3. Market Revenue and Forecast, by Application (2020-2032)

13.5.7.4. Market Revenue and Forecast, by Technology (2020-2032)

13.5.7.5. Market Revenue and Forecast, by End User (2020-2032)

Chapter 14. Company Profiles

14.1. Caladrius

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. CELGENE CORPORATION

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. ReNeuron Group plc

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Virgin Health Bank

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Opexa Therapeutics, Inc

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Pluristem Therapeutics Inc

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. STEMCELL Technologies Inc.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Biovault family

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Precious Cells International Ltd

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Mesoblast Ltd

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

 

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers